Status:
COMPLETED
Pharmacogenetics of Acenocoumarol
Lead Sponsor:
University Hospital, Geneva
Conditions:
Thromboembolic Diseases
Eligibility:
All Genders
18+ years
Brief Summary
The use of oral anticoagulation is marked by an elevated risk of adverse drug events (ADE) due to a narrow therapeutic window leading to important medical and economical consequences. The risk of ADE ...
Eligibility Criteria
Inclusion
- Every patients with requiring acenocoumarol therapy for at least 4 weeks and a target INR in the low intensity range (INR range 2-3)
- Age ≥ 18 years
- Signed informed consent
Exclusion
- Severe cognitive impairment
- Previous or current treatment with any coumarin
Key Trial Info
Start Date :
November 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2012
Estimated Enrollment :
115 Patients enrolled
Trial Details
Trial ID
NCT01492777
Start Date
November 1 2008
End Date
March 1 2012
Last Update
June 21 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospitals
Geneva, Switzerland, 1211